Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
- Citation:
- J Gastrointest Cancer vol 38 (2-4) 87-94
- Year:
- 2007
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 551
- Children:
- None
- Pharmas:
- Grants:
- CA-25224, CA-35103, CA-35113, CA-35119, CA-35267, CA-35269, CA-35448, CA-37404, CA-45450, CA-52352, CA-60276, CA35431
- Corr. Author:
- Steven R Alberts
- Authors:
- Steven R Alberts Jonathan R Sande Nathan R Foster Fernando J Quevedo Robert R McWilliams John W Kugler Tom R Fitch Anthony J Jaslowski
- Networks:
- Study
- NCCTG-N9943
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords:
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Deoxycytidine, Female, Gallbladder Neoplasms, Glutamates, Guanine, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Pemetrexed, Prognosis, Survival Rate, Treatment Outcome